Capital Impact Advisors LLC Purchases 1,240 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Capital Impact Advisors LLC increased its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Get Rating) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,966 shares of the medical instruments supplier’s stock after buying an additional 1,240 shares during the period. Merit Medical Systems comprises approximately 1.0% of Capital Impact Advisors LLC’s holdings, making the stock its 9th biggest holding. Capital Impact Advisors LLC’s holdings in Merit Medical Systems were worth $1,046,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its holdings in Merit Medical Systems by 65.6% in the 3rd quarter. CWM LLC now owns 593 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 235 shares in the last quarter. Wipfli Financial Advisors LLC acquired a new stake in shares of Merit Medical Systems in the 3rd quarter valued at about $40,000. Quantbot Technologies LP acquired a new stake in shares of Merit Medical Systems in the 1st quarter valued at about $43,000. Quadrant Capital Group LLC raised its stake in shares of Merit Medical Systems by 381.8% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,137 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 901 shares in the last quarter. Finally, Eagle Bay Advisors LLC raised its stake in shares of Merit Medical Systems by 87.0% in the 2nd quarter. Eagle Bay Advisors LLC now owns 1,870 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 870 shares in the last quarter. Institutional investors and hedge funds own 95.38% of the company’s stock.

Merit Medical Systems Price Performance

NASDAQ MMSI opened at $70.96 on Friday. Merit Medical Systems, Inc. has a 52 week low of $50.46 and a 52 week high of $76.14. The company has a current ratio of 2.40, a quick ratio of 1.19 and a debt-to-equity ratio of 0.16. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of 54.59, a price-to-earnings-growth ratio of 2.14 and a beta of 0.99. The company has a 50-day moving average price of $69.82 and a two-hundred day moving average price of $66.44.

Merit Medical Systems (NASDAQ:MMSI – Get Rating) last posted its earnings results on Wednesday, February 22nd. The medical instruments supplier reported $0.79 EPS for the quarter, topping the consensus estimate of $0.67 by $0.12. Merit Medical Systems had a net margin of 6.47% and a return on equity of 14.28%. The firm had revenue of $293.40 million during the quarter, compared to analysts’ expectations of $290.14 million. During the same quarter in the prior year, the firm earned $0.71 EPS. Merit Medical Systems’s quarterly revenue was up 5.4% on a year-over-year basis. Analysts forecast that Merit Medical Systems, Inc. will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Raymond James upped their target price on shares of Merit Medical Systems from $72.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, February 23rd. Canaccord Genuity Group lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $73.00 to $72.00 in a research note on Tuesday, December 20th. Needham & Company LLC increased their price objective on shares of Merit Medical Systems from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Thursday, February 23rd. StockNews.com started coverage on shares of Merit Medical Systems in a research note on Thursday. They set a “buy” rating on the stock. Finally, Barrington Research reiterated an “outperform” rating and set a $78.00 price objective on shares of Merit Medical Systems in a research note on Thursday, February 23rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average target price of $76.33.

Insiders Place Their Bets

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 1,483 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $70.17, for a total value of $104,062.11. Following the completion of the transaction, the chief executive officer now owns 1,012,069 shares in the company, valued at approximately $71,016,881.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Lynne Ward sold 11,585 shares of the stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $66.71, for a total value of $772,835.35. Following the completion of the transaction, the director now directly owns 5,964 shares in the company, valued at $397,858.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Fred P. Lampropoulos sold 1,483 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $70.17, for a total transaction of $104,062.11. Following the completion of the transaction, the chief executive officer now owns 1,012,069 shares of the company’s stock, valued at $71,016,881.73. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,068 shares of company stock worth $3,791,157. Insiders own 3.80% of the company’s stock.

About Merit Medical Systems

(Get Rating)

Merit Medical Systems, Inc engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.